Bristol Myers Squibb is the latest large pharma company to be making a major bet on artificial intelligence, announcing a sweeping agreement with Anthropic to deploy its AI tool Claude as the “shared ...

An Ipsen-commissioned survey has identified widespread problems with the transition from pediatric to adult healthcare, ...

After some six years at the post, Amgen’s finance chief is telegraphing his exit from the California pharma by early next ...

Gilead Sciences has broadened its partnership with Korean manufacturer Yuhan, agreeing to a 210 billion Korean won ($140 million) supply deal for active pharmaceutical ingredients (API) for an ...

Takeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case and ordered the ...

BeOne Medicines has tapped former professional soccer goalkeeper Tim Howard as the face of its first major corporate campaign ...

Tarsus Pharmaceuticals has spent the past three years marketing its way out of a largely unknown but stigmatized condition: ...

Even as a new drug pricing specter rears its head in President Donald Trump’s “Most Favored Nation” policies, drugmakers ...

As Eli Lilly moves to set up a mammoth manufacturing facility in Houston, it’s not the only U.S. pharma juggernaut with an ...

Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA approvals to treat early breast cancer. But ...

Over the last 18 months, Merck and Kelun-Biotech have notched four approvals in China for their TROP2-directed antibody-drug ...

A Novartis cross-border partnership is turning into a standoff. | A Novartis cross-border partnership is turning into a ...